Nothing Special   »   [go: up one dir, main page]

Attridge et al., 2014 - Google Patents

IL-21 Promotes CD4 T Cell Responses by Phosphatidylinositol 3-Kinase–Dependent Upregulation of CD86 on B Cells

Attridge et al., 2014

View HTML
Document ID
14799233530380223385
Author
Attridge K
Kenefeck R
Wardzinski L
Qureshi O
Wang C
Manzotti C
Okkenhaug K
Walker L
Publication year
Publication venue
The Journal of Immunology

External Links

Snippet

The cytokine IL-21 is a potent immune modulator with diverse mechanisms of action on multiple cell types. IL-21 is in clinical use to promote tumor rejection and is an emerging target for neutralization in the setting of autoimmunity. Despite its clinical potential, the …
Continue reading at journals.aai.org (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Similar Documents

Publication Publication Date Title
Attridge et al. IL-21 Promotes CD4 T Cell Responses by Phosphatidylinositol 3-Kinase–Dependent Upregulation of CD86 on B Cells
López-Cantillo et al. CAR-T cell performance: how to improve their persistence?
Qin et al. Insights into the molecular mechanisms of T follicular helper-mediated immunity and pathology
Barsheshet et al. CCR8+ FOXp3+ Treg cells as master drivers of immune regulation
Das et al. Tim‐3 and its role in regulating anti‐tumor immunity
Tian et al. The role of GITR/GITRL interaction in autoimmune diseases
Zingoni et al. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions
Spolski et al. Interleukin-21: basic biology and implications for cancer and autoimmunity
Mizui et al. Targeting regulatory T cells to treat patients with systemic lupus erythematosus
Leonard et al. IL-21 signaling in immunity
Nair et al. CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment
Matsumoto et al. Overexpression of cytotoxic T-lymphocyte–associated antigen-4 prevents atherosclerosis in mice
Wang et al. The four types of Tregs in malignant lymphomas
Zhu et al. Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation
Orabona et al. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86
Liu et al. IL‐27 enhances the survival of tumor antigen‐specific CD8+ T cells and programs them into IL‐10‐producing, memory precursor‐like effector cells
Dobrzanski Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy
Gao et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression
Ramsay Immune checkpoint blockade immunotherapy to activate anti‐tumour T‐cell immunity
Shi et al. Reciprocal regulation between natural killer cells and autoreactive T cells
Oberschmidt et al. Redirected primary human chimeric antigen receptor natural killer cells as an “off-the-shelf immunotherapy” for improvement in cancer treatment
Taylor et al. Glycogen synthase kinase 3 inactivation compensates for the lack of CD28 in the priming of CD8+ cytotoxic T-cells: Implications for anti-PD-1 immunotherapy
Wu et al. TLR ligand induced IL-6 counter-regulates the anti-viral CD8+ T cell response during an acute retrovirus infection
Joeris et al. Intestinal cDC1 drive cross-tolerance to epithelial-derived antigen via induction of FoxP3+ CD8+ Tregs
Fujimura et al. CD4 T cell-intrinsic IL-2 signaling differentially affects Th1 and Th17 development